← Leaderboards
Joshua (chuck) Harrell
Virginia Commonwealth University
$3,090,169
Attributed
$3,090,169
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,216,605 · 4
By mechanism
U54$3,953,510 · 2
R01$1,868,264 · 1
R21$394,831 · 1
Top collaborators
- Jose G. Trevino4 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Raphael Mechoulam$776,153
- Devanand Sarkar$13,330,601
- Kenneth Seedman Kendler$36,426,058
- Brien P Riley$7,350,297
- Zhongming Zhao$10,491,216
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorResponseMalignant Breast NeoplasmGrowthGenomicsNeoplasm MetastasisGeneticPatient Derived Xenograft ModelTriple-Negative Invasive Breast CarcinomaProteomicsPharmaceutical PreparationsPathway InteractionsMammary NeoplasmsTranscriptome SequencingCellsCessation Of LifeTranslatingOrganClinicCytotoxicIn VitroInnovationGenesCytotoxicity
Grant awards (17)
United for Health Equity - Living PDX Program (U4HELPP)$1,003,591
U54 · FY2025 · CA
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases$286,874
U54 · FY2025 · CA · contact PI
United for Health Equity - Living PDX Program (U4HELPP)$960,065
U54 · FY2024 · CA
Circumventing acquired carboplatin resistance in triple-negative breast cancers$330,123
R01 · FY2024 · CA · contact PI
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases$254,405
U54 · FY2024 · CA · contact PI
United for Health Equity - Living PDX Program (U4HELPP)$131,820
U54 · FY2024 · CA
Circumventing acquired carboplatin resistance in triple-negative breast cancers$63,064
R01 · FY2024 · CA · contact PI
Circumventing acquired carboplatin resistance in triple-negative breast cancers$61,133
R01 · FY2024 · CA · contact PI
United for Health Equity - Living PDX Program (U4HELPP)$1,030,960
U54 · FY2023 · CA
Circumventing acquired carboplatin resistance in triple-negative breast cancers$340,547
R01 · FY2023 · CA · contact PI
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases$285,795
U54 · FY2023 · CA · contact PI
Characterization of metastasis models derived from breast cancer patients of African descent$213,383
R21 · FY2023 · CA · contact PI
Circumventing acquired carboplatin resistance in triple-negative breast cancers$34,436
R01 · FY2023 · CA · contact PI
Circumventing acquired carboplatin resistance in triple-negative breast cancers$340,547
R01 · FY2022 · CA · contact PI
Characterization of metastasis models derived from breast cancer patients of African descent$181,448
R21 · FY2022 · CA · contact PI
Circumventing acquired carboplatin resistance in triple-negative breast cancers$347,497
R01 · FY2021 · CA · contact PI
Circumventing acquired carboplatin resistance in triple-negative breast cancers$350,917
R01 · FY2020 · CA · contact PI